Correlation Between Dr Reddys and Assertio Therapeutics
Can any of the company-specific risk be diversified away by investing in both Dr Reddys and Assertio Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Dr Reddys and Assertio Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Dr Reddys Laboratories and Assertio Therapeutics, you can compare the effects of market volatilities on Dr Reddys and Assertio Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Dr Reddys with a short position of Assertio Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Dr Reddys and Assertio Therapeutics.
Diversification Opportunities for Dr Reddys and Assertio Therapeutics
0.8 | Correlation Coefficient |
Very poor diversification
The 3 months correlation between RDY and Assertio is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Dr Reddys Laboratories and Assertio Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Assertio Therapeutics and Dr Reddys is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Dr Reddys Laboratories are associated (or correlated) with Assertio Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Assertio Therapeutics has no effect on the direction of Dr Reddys i.e., Dr Reddys and Assertio Therapeutics go up and down completely randomly.
Pair Corralation between Dr Reddys and Assertio Therapeutics
Considering the 90-day investment horizon Dr Reddys Laboratories is expected to under-perform the Assertio Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Dr Reddys Laboratories is 3.72 times less risky than Assertio Therapeutics. The stock trades about -0.28 of its potential returns per unit of risk. The Assertio Therapeutics is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest 106.00 in Assertio Therapeutics on August 24, 2024 and sell it today you would lose (9.00) from holding Assertio Therapeutics or give up 8.49% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Strong |
| Accuracy | 100.0% |
| Values | Daily Returns |
Dr Reddys Laboratories vs. Assertio Therapeutics
Performance |
| Timeline |
| Dr Reddys Laboratories |
| Assertio Therapeutics |
Dr Reddys and Assertio Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Dr Reddys and Assertio Therapeutics
The main advantage of trading using opposite Dr Reddys and Assertio Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Dr Reddys position performs unexpectedly, Assertio Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Assertio Therapeutics will offset losses from the drop in Assertio Therapeutics' long position.| Dr Reddys vs. Pacira BioSciences, | Dr Reddys vs. Phibro Animal Health | Dr Reddys vs. Collegium Pharmaceutical | Dr Reddys vs. ANI Pharmaceuticals |
| Assertio Therapeutics vs. Amneal Pharmaceuticals, Class | Assertio Therapeutics vs. Lifecore Biomedical | Assertio Therapeutics vs. Ironwood Pharmaceuticals | Assertio Therapeutics vs. Neurocrine Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |